Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

被引：3
|
作者：
George, S.
Blay, J. Y.
Casali, P. G.
Le Cesne, A.
DePrimo, S. E.
Harmon, C. S.
Law, C. N.
Tassell, V.
Baum, C. M.
Demetri, G. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Inst Gustave Roussy, Villejuif, France
[5] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.10554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10554
引用
收藏
页数：1
相关论文
共 28 条
  • [21] Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
    Krzakowski, Maciej Jerzy
    Lu, Shun
    Cousin, Sophie
    Smit, Egbert F.
    Springfeld, Christoph
    Goto, Koichi
    Garrido, Pilar
    Chung, Christine H.
    Lin, Jessica Jiyeong
    Bray, Victoria J.
    Pitcher, Bethany
    Zeuner, Harald
    Patel, Siddhartha
    Bordogna, Walter
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors
    Delord, J.
    Houde, N.
    Awada, A.
    Taamma, A.
    Faivre, S. J.
    Besse-Hammer, T.
    Italiano, A.
    Vignaud, C.
    Donica, M.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.
    Harris, Samuel John
    Luken, Maria Jose De Miguel
    Perez, Desamparados Roda
    Lopez, Raquel Perez
    Parmar, Mona
    Prathapan, Vasanthi
    Hassam, Hasina
    Turner, Alison Joanne
    Fandos, Sonia Serrano
    Hall, Emma
    Tovey, Holly
    Tunariu, Nina
    Lopez, Juanita Suzanne
    Yap, Timothy Anthony
    De Bono, Johann S.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies
    Sheng, Xinan
    Jin, Jie
    He, Zhisong
    Huang, Yiran
    Zhou, Ai-Ping
    Wang, Jinwan
    Ren, Xiu-Bao
    Ye, Dingwei
    Zhang, Xu
    Qin, Shukui
    Zhou, Fang-Jian
    Guo, Yanfang
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
    Mckean, M. A.
    Lakhani, N. J.
    Arkenau, H-T.
    Symeonides, S.
    Evans, T. R. J.
    Lim, E. A.
    Fontana, E.
    Bupathi, M.
    Mclaren, A.
    Chandana, S. R.
    Ding, T-E.
    Rotolo, J.
    Capiaux, G.
    Michel, R.
    Kaesshaefer, S.
    Bexon, A.
    Falchook, G. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S592 - S592
  • [26] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results
    von Weikersthal, Fischer L.
    Vervenne, W. L.
    Goebell, P. J.
    Eichelberg, C.
    Freier, W.
    De Santis, M.
    Zimmermann, U.
    Bos, M. M. E. M. M.
    Trojan, L.
    Lerchenmueller, C.
    Schenck, M.
    Staehler, M.
    Floercken, A.
    Pahernik, S.
    Los, M.
    van Arkel, C.
    Schirrmacher-Memmel, S.
    Michel, M. S.
    ONKOLOGIE, 2012, 35 : 237 - 237
  • [27] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.
    Michel, Maurice Stephan
    Vervenne, Walter
    Goebell, Peter J.
    Von Weikersthal, Ludwig Fischer
    Freier, Werner
    De Santis, Maria
    Zimmermann, Uwe
    Bos, Monique M. E. M.
    Trojan, Lutz
    Lerchenmuller, Christian A.
    Schenk, Marcus
    Staehler, Michael D.
    Floercken, Anne
    Pahernik, Sascha
    Los, Maartje
    Van Arkel, Cornelis
    Schirrmacher-Memmel, Silke
    Eichelberg, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] PIPA: A phase Ib study of selective β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers-Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
    Lopez, Juanita Suzanne
    SelviMiralles, Manuel
    Ameratunga, Malaka
    Minchom, Anna
    Pascual, Javier
    Banerji, Udai
    Bye, Hannah
    Raynaud, Florence I.
    Swales, Karen E.
    Malia, Jason
    Hubank, Michael
    Garcia-Murillas, Isaac
    Parmar, Mona
    Ward, Sarah Emily
    Finneran, Laura
    Hall, Emma
    Turner, Alison Joanne
    De Bono, Johann S.
    Yap, Timothy A.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
123